Media stories about Vanda Pharmaceuticals (NASDAQ:VNDA) have been trending positive on Thursday, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vanda Pharmaceuticals earned a news impact score of 0.27 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.0833443804196 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news stories that may have effected Accern Sentiment’s analysis:
- Healthcare stock Trending Alert – Vanda Pharmaceuticals Inc. (VNDA) – Nasdaq Fortune (press release) (nasdaqfortune.com)
- ETFs with exposure to Vanda Pharmaceuticals, Inc. : December 26, 2017 (finance.yahoo.com)
- Jefferies Group Comments on Vanda Pharmaceuticals Inc.’s FY2019 Earnings (VNDA) (americanbankingnews.com)
- Vanda Pharmaceuticals (VNDA) Upgraded to “Hold” by BidaskClub (americanbankingnews.com)
- Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017 (finance.yahoo.com)
Shares of Vanda Pharmaceuticals (VNDA) opened at $15.25 on Thursday. The firm has a market capitalization of $682.90, a P/E ratio of -47.66 and a beta of 1.28. Vanda Pharmaceuticals has a fifty-two week low of $11.90 and a fifty-two week high of $18.99.
A number of equities analysts recently issued reports on the company. Zacks Investment Research downgraded Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 5th. Oppenheimer reaffirmed a “buy” rating and issued a $21.00 price target on shares of Vanda Pharmaceuticals in a report on Thursday, September 14th. Piper Jaffray Companies upped their price target on Vanda Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a report on Thursday, September 14th. BidaskClub raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Finally, ValuEngine raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, December 20th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Vanda Pharmaceuticals has a consensus rating of “Buy” and an average target price of $21.50.
TRADEMARK VIOLATION WARNING: “Favorable Press Coverage Somewhat Unlikely to Impact Vanda Pharmaceuticals (VNDA) Stock Price” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.com-unik.info/2017/12/28/favorable-press-coverage-somewhat-unlikely-to-impact-vanda-pharmaceuticals-vnda-stock-price.html.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.